Who is sponsoring NCT06567743?

NCT06567743 is sponsored by CG Oncology, Inc..

What drugs are being tested in NCT06567743?

Interventions in NCT06567743: Cretostimogene Grenadenorepvec.

What condition does NCT06567743 study?

NCT06567743 studies High-Risk Non-Muscle-Invasive Bladder Cancer.

Is NCT06567743 still recruiting?

NCT06567743 is currently recruiting now. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT06567743

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting now Phase 2 Last updated 8 April 2026

What this trial tests

Phase 2 trial testing Cretostimogene Grenadenorepvec in High-Risk Non-Muscle-Invasive Bladder Cancer in 325 participants. Currently enrolling.

Timeline

16 September 2024

Primary endpoint
31 March 2027

30 December 2027

Quick facts

Lead sponsor	CG Oncology, Inc.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	325
Start date	16 September 2024
Primary completion	31 March 2027
Estimated completion	30 December 2027
Sites	65 locations across United States

Drugs / interventions tested

Cretostimogene Grenadenorepvec — full drug profile →

Conditions studied

High-Risk Non-Muscle-Invasive Bladder Cancer — all drugs for High-Risk Non-Muscle-Invasive Bladder Cancer →

Sponsor

CG Oncology, Inc. — full company profile →

Who can join

18 and older, any sex, with High-Risk Non-Muscle-Invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer
Grier A, Zhong J, Basourakos S, Calaway A, et al · · 2026
Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure: a systematic review.
Soma T, Takemura K, Toide M, Ito M, et al · · 2026 · PMID 41635525 · DOI 10.1136/bmjonc-2025-000753
Oncolytic adenoviruses in bladder and kidney cancers: emerging strategies and next frontiers.
Yao J, Shayakhmetov DM. · · 2025 · PMID 41445946 · DOI 10.3389/fmicb.2025.1729087
Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions.
Pinton P. · · 2025 · PMID 41300998 · DOI 10.3390/cancers17223631
Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder.
Escobar D, Doshi C, Zahir M, Daneshmand S. · · 2026 · PMID 40549001 · DOI 10.1007/s00120-025-02625-2

Verify or expand the search:

Other trials of Cretostimogene Grenadenorepvec

Trials testing the same drug.

NCT07283835 — Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Gue · Phase 2 · recruiting
NCT04452591 — Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Gue · Phase 3 · active not recruiting
NCT06443944 — An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG · available

Other CG Oncology, Inc. trials

Trials by the same sponsor.

NCT04387461 — Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus · Phase 2 · completed
NCT04452591 — Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Gue · Phase 3 · active not recruiting
NCT06443944 — An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG · available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06567743 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CG Oncology, Inc.
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06567743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing